Table 5 Clinical outcomes.
From: Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes
CD patients (n = 31) | Control patients (n = 124) | p-value | |||
|---|---|---|---|---|---|
Frequency (%) or median (IQR) | Valid cases | Frequency (%) or median (IQR) | Valid cases | ||
Length of stay | 8.0 (4.5, 13.5) | 31 | 10.0 (7.0, 17.0) | 124 | 0.220 |
Admission to ICU | 16 (51.6%) | 31 | 56 (45.2%) | 124 | 0.658 |
Time from admission to ICU (days) | 1.0 (0.0, 2.0) | 16 | 0.5 (0.0, 2.0) | 56 | 0.891 |
Days in ICU | 6.0 (2.0, 11.2) | 16 | 7.5 (4.0, 14.0) | 56 | 0.352 |
Thromboembolic events | 0 (0.0%) | 31 | 7 (5.6%) | 124 | 0.346 |
Mechanical ventilation | 10 (32.3%) | 31 | 45 (36.3%) | 124 | 0.834 |
Acute kidney injury | 9 (37.5%) | 24 | 45 (41.7%) | 108 | 0.884 |
RRT | 5 (16.1%) | 31 | 21 (16.9%) | 124 | > 0.999 |
Sepsis | 6 (19.4%) | 31 | 24 (19.4%) | 124 | > 0.999 |
Nosocomial infection | 3 (9.7%) | 31 | 24 (19.4%) | 124 | 0.314 |
Acute heart failure | 2 (6.5%) | 31 | 5 (4.0%) | 124 | 0.628 |
Acute respiratory distress | 9 (29.0%) | 31 | 44 (35.5%) | 124 | 0.641 |
Death | 10 (32.3%) | 31 | 38 (30.6%) | 124 | > 0.999 |
